NCT04506073View on ClinicalTrials.gov

Phase IIa Randomized Placebo Controlled Trial: Mesenchymal Stem Cells as a Disease-modifying Therapy for Idiopathic Parkinson's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

November 9, 2020

Primary Completion Date

July 30, 2023

Study Completion Date

July 30, 2023

Conditions
Parkinson's Disease
Interventions
DRUG

Mesenchymal Stem Cells

1 dose is 10 X 10\^6 MSC/kg

DRUG

Placebo

Placebo will be identical to the investigational product but will not contain mesenchymal stem cells (MSCs).

Trial Locations (1)

77030

The University of Texas Health Science Center at Houston, Houston

All Listed Sponsors
collaborator

Michael J. Fox Foundation for Parkinson's Research

OTHER

lead

The University of Texas Health Science Center, Houston

OTHER

NCT04506073 - Phase IIa Randomized Placebo Controlled Trial: Mesenchymal Stem Cells as a Disease-modifying Therapy for Idiopathic Parkinson's Disease | Biotech Hunter | Biotech Hunter